AstraZeneca reported positive Phase 3 results for tozorakimab in chronic obstructive pulmonary disease (COPD), saying the antibody met primary goals in two trials (Oberon and Titania). The company said the data support efficacy across a broader patient mix than expected, spanning former and current smokers and patients across eosinophil counts. The update arrives after a mixed late-stage history for IL-33–blocking approaches in the class, with analysts noting that similarly acting programs from Roche and partners had struggled. AstraZeneca did not provide complete data in the initial release and plans to disclose details at an upcoming medical meeting. If confirmed in full datasets and follow-on regulatory work, tozorakimab could expand the market for COPD biologics beyond eosinophil-restricted use cases, changing treatment selection for a sizable subgroup.